EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Clinical, electrocardiographic, and echocardiographic parameters associated with the development of pacing and implantable cardioverter-defibrillator indication in patients with transthyretin amyloid cardiomyopathy

Yusei Kawahara, Hisanori Kanazawa iD, Seiji Takashio iD, Yuichiro Tsuruta iD, Hitoshi Sumi iD, Takuya Kiyama iD, Shozo Kaneko iD, Miwa Ito iD, Tadashi Hoshiyama iD, Kyoko Hirakawa iD, Masanobu Ishii iD, Noriaki Tabata iD und 13 weitere

Europace · 2023

DOI: 10.1093/europace/euad105 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Europace, 2023. Verfasst von Yusei Kawahara und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556, Japan. Hauptthemen laut MEDLINE: Defibrillators, Implantable, Atrioventricular Block, Cardiomyopathies. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

This study aimed to identify factors for attention leading to future pacing device implantation (PDI) and reveal the necessity of prophylactic PDI or implantable cardioverter-defibrillator (ICD) implantation in transthyretin amyloid cardiomyopathy (ATTR-CM) patients. Methods and results This retrospective single-center observational study included consecutive 114 wild-type ATTR-CM (ATTRwt-CM) and 50 hereditary ATTR-CM (ATTRv-CM) patients, neither implanted with a pacing device nor fulfilling indications for PDI at diagnosis. As a study outcome, patient backgrounds were compared with and without future PDI, and the incidence of PDI in each conduction disturbance was examined. Furthermore, appropriate ICD therapies were investigated in all 19 patients with ICD implantation. PR-interval ≥220 msec, interventricular septum (IVS) thickness ≥16.9 mm, and bifascicular block were significantly associated with future PDI in ATTRwt-CM patients, and brain natriuretic peptide ≥35.7 pg/mL, IVS thickness ≥11.3 mm, and bifascicular block in ATTRv-CM patients. The incidence of subsequent PDI in patients with bifascicular block at diagnosis was significantly higher than that of normal atrioventricular (AV) conduction in both ATTRwt-CM [hazard ratio (HR): 13.70, P = 0.019] and ATTRv-CM (HR: 12.94, P = 0.002), whereas that of patients with first-degree AV block was neither (ATTRwt-CM: HR: 2.14, P = 0.511, ATTRv-CM: HR: 1.57, P = 0.701). Regarding ICD, only 2 of 16 ATTRwt-CM and 1 of 3 ATTRv-CM patients received appropriate anti-tachycardia pacing or shock therapy, under the number of intervals to detect for ventricular tachycardia of 16–32.

Conclusions

According to our retrospective single-center observational study, prophylactic PDI did not require first-degree AV block in both ATTRwt-CM and ATTRv-CM patients, and prophylactic ICD implantation was also controversial in both ATTR-CM. Larger prospective, multi-center studies are necessary to confirm these results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Defibrillators, ImplantableAtrioventricular BlockCardiomyopathiesHumansPrealbuminRetrospective StudiesProspective StudiesCardiac Conduction System DiseaseBundle-Branch BlockEchocardiography

Stichwörter der Autor:innen

Transthyretin amyloid cardiomyopathy • Pacing device • Implantable cardioverter…

Substanzen

Prealbumin

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556, Japan.
  • Department of Cardiac Arrhythmias, Kumamoto University, Kumamoto, Japan, 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556, Japan.

ORCID-Profile: Hisanori Kanazawa, Seiji Takashio, Yuichiro Tsuruta, Hitoshi Sumi, Takuya Kiyama, Shozo Kaneko, Miwa Ito, Tadashi Hoshiyama, Kyoko Hirakawa, Masanobu Ishii, Noriaki Tabata, Kenshi Yamanaga, Koichiro Fujisue, Shinsuke Hanatani, Daisuke Sueta, Yuichiro Arima, Satoshi Araki, Taishi Nakamura, Kenichi Matsushita, Hiroaki Kawano, Kenichi Tsujita

Zitieren

APA

Kawahara, Y., Kanazawa, H., Takashio, S., Tsuruta, Y., Sumi, H., Kiyama, T., Kaneko, S., Ito, M., Hoshiyama, T., Hirakawa, K., Ishii, M., Tabata, N., Yamanaga, K., Fujisue, K., Hanatani, S., Sueta, D., Arima, Y., Araki, S., Usuku, H., …, & Tsujita, K. (2023). Clinical, electrocardiographic, and echocardiographic parameters associated with the development of pacing and implantable cardioverter-defibrillator indication in patients with transthyretin amyloid cardiomyopathy. Europace. https://doi.org/10.1093/europace/euad105

Vancouver

Kawahara Y, Kanazawa H, Takashio S, Tsuruta Y, Sumi H, Kiyama T, et al. Clinical, electrocardiographic, and echocardiographic parameters associated with the development of pacing and implantable cardioverter-defibrillator indication in patients with transthyretin amyloid cardiomyopathy. Europace. 2023. doi:10.1093/europace/euad105

BibTeX
@article{Kawahara2023,
  author = {Kawahara, Yusei and Kanazawa, Hisanori and Takashio, Seiji and Tsuruta, Yuichiro and Sumi, Hitoshi and Kiyama, Takuya and Kaneko, Shozo and Ito, Miwa and Hoshiyama, Tadashi and Hirakawa, Kyoko and Ishii, Masanobu and Tabata, Noriaki and Yamanaga, Kenshi and Fujisue, Koichiro and Hanatani, Shinsuke and Sueta, Daisuke and Arima, Yuichiro and Araki, Satoshi and Usuku, Hiroki and Nakamura, Taishi and Yamamoto, Eiichiro and Soejima, Hirofumi and Matsushita, Kenichi and Kawano, Hiroaki and Tsujita, Kenichi},
  title = {Clinical, electrocardiographic, and echocardiographic parameters associated with the development of pacing and implantable cardioverter-defibrillator indication in patients with transthyretin amyloid cardiomyopathy},
  journal = {Europace},
  year = {2023},
  doi = {10.1093/europace/euad105}
}
Kostenlos starten →